Literature DB >> 27769871

Reevaluation of MAML2 fusion-negative mucoepidermoid carcinoma: a subgroup being actually hyalinizing clear cell carcinoma of the salivary gland with EWSR1 translocation.

Min-Shu Hsieh1, Hsuang Wang2, Yi-Hsuan Lee2, Jenq-Yuh Ko3, Yih-Leong Chang4.   

Abstract

Hyalinizing clear cell carcinoma (HCCC) is a rare salivary gland tumor with a specific EWSR1-ATF1 fusion gene and can have mucin production. Mucoepidermoid carcinoma (MEC) with a clear cell component is its morphologic mimic. Using MAML2 fluorescence in situ hybridization (FISH), a total of 49 MEC cases were separated into MAML2 fusion-positive (32 cases) and MAML2 fusion-negative groups (17 cases). This study used EWSR1 FISH to investigate MAML2 fusion-negative cases to identify previously unrecognized HCCC. Among 17 MAML2 fusion-negative cases, 3 had rearrangement of the EWSR1 gene and were reclassified as HCCC. Including 5 previously diagnosed HCCC cases, these 8 HCCC cases had a male-to-female ratio of 1:7, and most (7/8) tumors arose from oral minor salivary glands in the oral cavity (tongue base and palate). EWSR1-ATF1 fusion was confirmed by FISH in all 8 HCCC cases. The histologic features between genetically confirmed HCCC and MEC were compared. HCCC was significantly associated with minor salivary gland involvement, a discrepancy between low-grade cytology and intermediate- to high-grade histology using the MEC grading system, and absence of both epidermoid cells with abundant cytoplasm and goblet cells lining cysts or forming clusters. Clear cells and a hyalinized stroma were not specific for HCCC. HCCC may be erroneously classified as MEC because clear cells may be a minor histologic component and mucin production is not uncommon. Previously diagnosed MEC cases should be reevaluated, especially those arising from minor salivary glands or without MAML2 fusion. Careful histologic evaluation with supporting molecular testing can facilitate pathologic diagnoses.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATF1; EWSR1; Hyalinizing clear cell carcinoma; MAML2; Mucoepidermoid carcinoma

Mesh:

Substances:

Year:  2016        PMID: 27769871     DOI: 10.1016/j.humpath.2016.06.029

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

Review 1.  Challenges in Minor Salivary Gland Biopsies: A Practical Approach to Problematic Histologic Patterns.

Authors:  Lisa M Rooper
Journal:  Head Neck Pathol       Date:  2019-03-18

2.  Mucoepidermoid Carcinoma: A Comparison of Histologic Grading Systems and Relationship to MAML2 Rearrangement and Prognosis.

Authors:  Nicole A Cipriani; Jonathan J Lusardi; James McElherne; Alexander T Pearson; Andrea D Olivas; Carrie Fitzpatrick; Mark W Lingen; Elizabeth A Blair
Journal:  Am J Surg Pathol       Date:  2019-07       Impact factor: 6.394

3.  Clear Cell Carcinoma of Salivary Glands Is Frequently p16 Positive: A Pitfall in the Interpretation of Oropharyngeal Biopsies.

Authors:  Justin A Bishop; Lisa M Rooper; Simion I Chiosea; William H Westra
Journal:  Am J Surg Pathol       Date:  2018-03       Impact factor: 6.394

4.  Does Nodal Metastasis and Perineural Invasion Affect Local Control in Hyalinizing Clear Cell Carcinoma of the Oral Cavity? A Case Report with Long Term Follow-Up.

Authors:  John M Le; Darya Gubarev; Yedeh Ying; Anthony Morlandt
Journal:  Head Neck Pathol       Date:  2020-07-27

5.  Nasopharyngeal Hyalinizing Clear Cell Carcinoma: A Case Report and Review of the Literature.

Authors:  Madison J Malfitano; Meghan N Norris; Wesley H Stepp; Griffin D Santarelli; T Danielle Samulski; Brent A Senior; Charles S Ebert; Brian D Thorp; Adam M Zanation; Adam J Kimple
Journal:  Allergy Rhinol (Providence)       Date:  2019-11-20

6.  Clinicopathological and molecular study of 10 salivary gland clear cell carcinomas, with emphasis on rare cases with high grade transformation and occurring in uncommon sites.

Authors:  Lanlan Xuan; Suxia Wang; Jianguo Wei; Jianwei Yuan; Honggang Liu
Journal:  Diagn Pathol       Date:  2022-01-30       Impact factor: 2.644

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.